魏文嵩

[摘要]目的 探討表柔比星聯(lián)合紫杉醇脂質(zhì)體的新輔助化療方法治療三陰性乳腺癌的臨床效果。方法 選取2015年6月～2016年6月我院收治的80例三陰性乳腺癌患者作為研究對(duì)象，隨機(jī)分為觀察組和對(duì)照組，各40例。對(duì)照組單獨(dú)給予表柔比星新輔助化療，觀察組采用紫杉醇脂質(zhì)體、表柔比星聯(lián)合新輔助化療。比較兩組治療前后的腫瘤直徑、乳腺癌易感基因（BRCA1）水平、叉頭框蛋白A1（FOXA1）水平、臨床療效及治療過(guò)程中的不良反應(yīng)發(fā)生率。結(jié)果 觀察組的總有效率為82.50%，顯著高于對(duì)照組的70.00%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組的不良反應(yīng)發(fā)生率比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）。兩組治療后的腫瘤直徑、BRCA1和FOXA1水平均低于治療前，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組治療后的腫瘤直徑、BRCA1和FOXA1水平顯著優(yōu)于對(duì)照組治療后，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 采用紫杉醇脂質(zhì)體、表柔比星聯(lián)合新輔助化療治療三陰性乳腺癌安全可靠，不增加不良反應(yīng)，患者的耐受性較好，具有較高的臨床應(yīng)用價(jià)值。

[關(guān)鍵詞]三陰性乳腺癌；表柔比星；紫杉醇脂質(zhì)體；新輔助化療；臨床療效

[中圖分類號(hào)] R737.9 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-4721（2016）12（b）-0065-03

Effects of the neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of triple negative breast cancer

WEI Wen-song

Department of the Third Galactophore，the Third Hospital of Nanchang City，Jiangxi Province，Nanchang 330009，China

[Abstract]Objective To explore the clinical efficacy of the neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of triple negative breast cancer （TNBC）.Methods 80 patients with TNBC in our hospital from June 2015 to June 2016 were selected and randomly divided into the observation group and the control group，40 cases in each group.The control group was given simple neoadjuvant chemotherapy of Epirubicin.The observation group was given neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel.The tumor diameter，breast cancer susceptibility gene （BRCA1） level，fork-box protein A1 （FOXA1） level before and after treatment and clinical efficacy，the incidence rate of adverse reaction were compared between the two groups.Results The total effective rate of the observation group was 82.50%，which was higher than 70.00% of the control group，with significant difference （P<0.05）.There was no significant difference in the incidence rate of adverse reaction between the two groups（P>0.05）.The tumor diameter，the level of BRCA1 and FOXA1 after treatment in the two group was lower than that before treatment，with significant difference （P<0.05）.The tumor diameter，the level of BRCA1 and FOXA1 after treatment in the observation group was better than that in the control group，with significant difference （P<0.05）.Conclusion The neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of TNBC is safe and reliable，with no increase of adverse reaction，and the patients have a higher degree of tolerance while being treated.It is highly significant in clinical application.